Effect of vedolizumab treatment on extraintestinal articular manifestations in patients with inflammatory bowel disease: meta-analysis
Vedolizumab treatment appears to be associated with a relatively low incidence of new or worsening joint EIMs. However, its effectiveness in improving joint manifestations is limited.
Authors
- Diego Casas Deza (ORCID: https://orcid.org/0000-0001-6883-8940)
- Santiago García‐López (ORCID: https://orcid.org/0000-0003-3970-5457)
- Carmen Yagüe-Caballero (ORCID: https://orcid.org/0009-0003-7771-6197)
- Camila Cuarán Cetina (ORCID: https://orcid.org/0009-0001-2600-0530)
Institutions
- Servicio Aragonés de Salud (ES)
- Hospital Universitario Miguel Servet (ES)
- Instituto de Investigación Sanitaria Aragón (ES)
Publication Details
- Journal
- Revista Española de Enfermedades Digestivas
- Published
- 2025-01-01
- DOI
- https://doi.org/10.17235/reed.2025.11419/2025
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00